<p>The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer</p>

Abstract

The CRP/albumin (Alb) ratio, a recently reported predictor, has shown value for prognosis in various human cancers. This study aimed to determine the prognostic value of baseline CRP/Alb and to explore the relevance between postchemotherapy CRP/Alb and the efficacy of chemotherapy in advanced pancreatic cancer patients. Patients and methods: Five hundred and ninety-five patients diagnosed with locally advanced or metastatic adenocarcinoma of the pancreas were enrolled. Cutoff Finder was used to calculate the best cutoff value for baseline CRP/Alb. The primary endpoint was overall survival, which was analyzed by Kaplan-Meier survival curves with 95% confidence intervals. The log rank test and Cox proportional hazard model were used to evaluate the univariate and multivariate analyses. Results: The optimal cutoff value for baseline CRP/Alb was determined to be 0.18. Both the baseline CRP/Alb (CRP/Alb≥0.18 vs. CRP/Alb<0.18, hazard ratio [HR] = 2.506; p<0.001) and postchemotherapy CRP/Alb (CRP/Alb≥0.18 vs. CRP/Alb<0.18, HR = 1.854; p =0.002) were significant predictors of overall survival according to multivariate analysis and were independent of other factors. Patients with a baseline and postchemotherapy CRP/ Alb ≥0.18 had the worst prognosis. Conclusion: CRP/Alb is a strong and useful indicator of prognosis for advanced pancreatic cancer. Both baseline and postchemotherapy CRP/Alb can be used in predicting the survival of patients and monitoring the effectiveness of chemotherapy in clinical practice.

Prognostic and Clinicopathological Significance of C-Reactive Protein to Albumin Ratio in Patients With Pancreatic Cancer: A Meta-Analysis

“…Seventeen studies were excluded after full-text review for insufficient data (n = 13), recruiting overlapping patients (n = 2), not focusing on pancreatic cancer (n = 1), and lack of pretreatment CAR measurement. Finally, the meta-analysis included a total of 11 studies 14 -24 comprising 2271 patients. The baseline characteristics of the included studies are shown in Table 1.…”

“…The baseline characteristics of the included studies are shown in Table 1. The studies were published from 2016 to 2019 from 5 countries, including Japan (n ¼ 4), 17,19,20,23 China (n ¼ 3), 15,16,22 Korea (n ¼ 2), 14,21 Italy (n ¼ 1), 18 and Austria (n ¼ 1). 24 The sample sizes ranged from 43 to 595, with a median of 188.…”

“…Six studies 15,16,19,[22][23][24] reported the relevance of CAR and clinicopathological characteristics including sex (male vs female), tumor location (head vs body or tail), disease stage (metastasis vs locally advanced), and pN stage (N1 vs N0). As shown in Figure 4 and…”

“…13 The CAR is a novel inflammation-based parameter that has been evaluated as a potential prognostic factor in pancreatic cancer. 14 -24 However, the results of previous relevant studies 14 -24 were inconsistent. To quantitatively and systematically clarify this issue, we identified relevant studies and performed a meta-analysis of the prognostic value of CAR in patients with pancreatic cancer.…”

Increased pretreatment C-reactive protein-to-albumin ratio predicts severe coronavirus disease 2019

“…An increased CAR indicates a poor clinical prognosis in patients undergoing percutaneous coronary intervention [31]. Recent studies showed that the CAR was predictive of disease progression and mortality in patients with gastric cancer, pancreatic cancer and non-small-cell lung cancer [13,22,32,33]. The results of the study by Miyamoto et al showed that the CAR was an independent factor that was predictive of two-week survival; in particular, the CAR is a useful tool for predicting survival times in end-stage patients with or without cancer [34].…”